Lucid Diagnostics Receives Notice Of Allowance From USPTO For Patent Application Covering Its Proprietary Method Of Using Methylation Of The Cyclin-A1 Gene To Help Detect Esophageal Precancer And Cancer
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method using methylation of the Cyclin-A1 gene to detect esophageal precancer and cancer.
October 15, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics has been granted a Notice of Allowance by the USPTO for a patent on its method to detect esophageal precancer and cancer, potentially enhancing its product offerings and market position.
The Notice of Allowance from the USPTO is a significant step towards securing a patent, which can enhance Lucid Diagnostics' competitive edge and product portfolio. This development is likely to positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PAVmed, the parent company of Lucid Diagnostics, may benefit indirectly from the USPTO's Notice of Allowance for Lucid's cancer detection method.
As the parent company of Lucid Diagnostics, PAVmed may experience positive effects from Lucid's progress in securing a patent, potentially enhancing its overall market value.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50